MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC)'s (ASX:MXC) Ron Lipsky, VP of Business Development & International Relations joins Proactive London's Katie Pilbeam about their partner AMC Holdings placing its first order a little over a month after signing a supply deal worth up to US$24mln over the next three years.
He explains how the US$3mln purchase order is for CimetrA, MGC’s curcumin and Boswellia compound, giving them exposure to three markets, 'we have three opportunities', he says.
At 110,000 units of CimetrA, this is the biggest single order the company has received for the product to date.